WallStreetZenWallStreetZen

NASDAQ: MXCT
Maxcyte Inc Stock Forecast, Predictions & Price Target

Analyst price target for MXCT

Based on 3 analysts offering 12 month price targets for Maxcyte Inc.
Min Forecast
$7.00+67.06%
Avg Forecast
$8.67+106.85%
Max Forecast
$11.00+162.53%

Should I buy or sell MXCT stock?

Based on 3 analysts offering ratings for Maxcyte Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MXCT stock forecasts and price targets.

MXCT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-13
lockedlocked$00.00+00.00%2024-03-13
lockedlocked$00.00+00.00%2023-11-29

1 of 1

Forecast return on equity

Is MXCT forecast to generate an efficient return?
Company
N/A
Industry
20.23%
Market
29.28%

Forecast return on assets

Is MXCT forecast to generate an efficient return on assets?
Company
N/A
Industry
10.62%

MXCT revenue forecast

What is MXCT's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$34.2M-17.29%
Avg 2 year Forecast
$43.9M+6.21%
MXCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MXCT revenue growth forecast

How is MXCT forecast to perform vs Medical Devices companies and vs the US market?
Company
-17.29%
Industry
7.6%
Market
13.86%
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MXCT vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
MXCT$4.19$8.67+106.85%Strong Buy
ZIMV$16.49$16.00-2.97%Sell
SRDX$29.34$59.00+101.09%Buy
RCEL$16.03$23.00+43.48%Strong Buy
BVS$5.20$8.00+53.85%Strong Buy

Maxcyte Stock Forecast FAQ

Is Maxcyte Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MXCT) stock is to Strong Buy MXCT stock.

Out of 3 analysts, 2 (66.67%) are recommending MXCT as a Strong Buy, 1 (33.33%) are recommending MXCT as a Buy, 0 (0%) are recommending MXCT as a Hold, 0 (0%) are recommending MXCT as a Sell, and 0 (0%) are recommending MXCT as a Strong Sell.

If you're new to stock investing, here's how to buy Maxcyte stock.

What is MXCT's revenue growth forecast for 2024-2025?

(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of -17.29% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.86%.

Maxcyte's revenue in 2024 is $41,288,000.On average, 2 Wall Street analysts forecast MXCT's revenue for 2024 to be $3,555,993,398, with the lowest MXCT revenue forecast at $3,457,071,180, and the highest MXCT revenue forecast at $3,654,915,615.

In 2025, MXCT is forecast to generate $4,566,041,303 in revenue, with the lowest revenue forecast at $4,227,623,190 and the highest revenue forecast at $4,904,459,415.

What is MXCT's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: MXCT) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of 10.62%.

What is MXCT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MXCT price target, the average MXCT price target is $8.67, with the highest MXCT stock price forecast at $11.00 and the lowest MXCT stock price forecast at $7.00.

On average, Wall Street analysts predict that Maxcyte's share price could reach $8.67 by Mar 13, 2025. The average Maxcyte stock price prediction forecasts a potential upside of 106.85% from the current MXCT share price of $4.19.

What is MXCT's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: MXCT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.